![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Places Clinical Hold on CD19-Specific CAR-T Phase 1 Trial
FDA Places Clinical Hold on CD19-Specific CAR-T Phase 1 Trial
![FDA_Logo_Blue_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Blue_2016.gif?t=1578316591&width=430)
June 20, 2018
The FDA imposed a clinical hold on a Phase 1 trial to evaluate CD19-specific CAR-T therapies.
Sponsor Ziophram Oncology is seeking to conduct the trial to evaluate CAR-T cells manufactured with its “Sleeping Beauty” technology as a potential treatment for relapsed or refractory CD19+ leukemias and lymphomas. The agency is requesting additional information relative to chemistry, manufacturing and controls.
Ziopharm said the hold will likely not affect timelines for the company’s planned second-generation clinical trial at the National Cancer Institute.
Upcoming Events
-
21Oct